St. Jude Children's Research Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, St. Jude Children's Research Hospital sits in the top decile of US sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count).
St. Jude Children's Research Hospital: 410 sponsored US clinical trials, 90 recruiting.
St. Jude Children's Research Hospital sponsors 410 registered US clinical trials on ClinicalTrials.gov, 90 of them currently recruiting, and 227 completed. 19 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sickle Cell Disease, with 17 trials.
Top-decile sponsor footprint
St. Jude Children's Research Hospital ranks in the top decile of sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
227 of 259 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
410 total, page 3 of 9
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
NCT05164016
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
NCT04733534
An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer
NCT04742751
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT04898894
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
NCT03597594
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131
Telehealth Based Intervention to Improve Functional Capacity in Survivors of Childhood Cancer With Significantly Limited Exercise Tolerance
NCT04714840
Social Experiences of Adolescents and Young Adults With Cancer
NCT04328350
Estimating Setup Uncertainty in Pediatric Proton Therapy Using Volumetric Images
NCT04125095
Patient-Reported Outcome Version of the Common Criteria for Adverse Events
NCT04050072
Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)
NCT04105530
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
NCT03541720
Exploring Adherence Monitoring in Sickle Cell Disease
NCT03708731
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
NCT03849651
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
NCT03573700
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
NCT03361020
Next Generation Pathogen Sequencing for Prediction of Adverse Events
NCT03226158
Evaluation of Proton Therapy in Pediatric Cancer Patients
NCT03223766
Social Emotional Development in Young Children With Cancer
NCT03086421
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT03164057
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03117751
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
NCT02790515
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
NCT02792582
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
NCT02553460
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
NCT02256137
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
NCT02114229
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
NCT02125786
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
NCT01946529
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
NCT01871766
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
NCT01920932
Therapy for Children With Advanced Stage Neuroblastoma
NCT01857934
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
NCT01878617
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
NCT01783535
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection
NCT01419067
Mature B-Cell Lymphoma And Leukemia Study III
NCT01046825
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
NCT00979238
Methionine PET/CT Studies In Patients With Cancer
NCT00840047
Stress, Adjustment And Growth In Children With Cancer And Their Parents
NCT01044160
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
NCT00846742
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
NCT00539591
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
NCT00602667
Radiation Therapy to Treat Musculoskeletal Tumors
NCT00186992
Muscle Aging Phenotypes in Childhood Cancer Survivors
NCT07531498
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
NCT07616154
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
NCT07514819
Real World Asparaginase Therapy Toxicity
NCT07008027
Insights From Bereaved Parents and Oncologists
NCT07663539
Liver Biopsy Following Gene Therapy For Hemophilia
NCT05932914
Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE
NCT07594392
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 86 |
| Phase 3 | 17 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the St. Jude Children's Research Hospital pipeline
90 recruiting of 410 indexed (22% open); 227 completed (55%).
Phase mix: 19 late (III/IV) vs 173 early (I/II) (early-phase heavy).
Top condition: Sickle Cell Disease (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
St. Jude Children's Research Hospital: open-pipeline peers nationwide
Peers matched on 410 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
St. Jude Children's Research Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 410 trials (± recruiting share)
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Rutgers, The State University of New Jersey · 413 trials · 26% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Northwell Health · 22% recruiting · 370 trials
- Vanda Pharmaceuticals · 22% recruiting · 68 trials
- Boston University Charles River Campus · 22% recruiting · 104 trials
- Regeneron Pharmaceuticals · 22% recruiting · 280 trials
Related
What to do with this St. Jude Children's Research Hospital page
410 registered trials is a research-attention snapshot, not an endorsement of St. Jude Children's Research Hospital or any single study.
- 90 of St. Jude Children's Research Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sickle Cell Disease is the condition St. Jude Children's Research Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sickle Cell Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
St. Jude Children's Research Hospital pipeline card: 410 registered trials from official public datasets.Report a data error.